ARTICLE | Financial News
Clinical hold sinks Advaxis shares
March 13, 2018 5:07 PM UTC
Advaxis Inc. (NASDAQ:ADXS) tumbled $0.26 (12%) to $1.95 on Tuesday after the company announced late Monday that FDA had placed a clinical hold on a Phase I/II trial of axalimogene filolisbac (ADXS11-001) (see BioCentury Extra, March 12). ...